title: [Long-term study of nipradilol ophthalmic solution in patients with normal-tension glaucoma].
abstract: OBJECTIVE
  We investigated the long-term clinical effects of a nipradilol ophthalmic solution on normal-tension glaucoma.
  
  
  METHODS
  Among normal tension glaucoma patients who consulted the Nara Medical University Hospital or 2 affiliated hospitals between November 2001 and August 2002, we prospectively examined intraocular pressure-decreasing effects, the deterioration of visual field defects, and the appearance of side effects in 46 patients who underwent single therapy with a nipradilol ophthalmic solution. We evaluated intraocular pressure at 6-month intervals. The deterioration of visual field defects was assessed based on a 3-dB or more decrease in the mean deviation measured using the Humphrey Field Analyzer 30-2 program.
  
  
  RESULTS
  The 60 months intraocular pressure value after administration of nipradilol ophthalmic solution was significantly lower than the pretreatment value. The deterioration of visual field defects was examined using the Kaplan-Meier life table. The survival rate after 60 months was 82.4%. In 4 of the 46 patients, administration of the nipradilol ophthalmic solution was discontinued due to side effects.
  
  
  CONCLUSIONS
  Long-term therapy with a nipradilol ophthalmic solution may be useful for treating normal-tension glaucoma.
authors.affiliation: Department of Ophthalmology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara-ken 634-8522, Japan. y-eiichi@mrh.biglobe.ne.jp
authors.forename: Eiichi
authors.initials: E
authors.lastname: Yukawa
authors.forename: Nobuto
authors.initials: N
authors.lastname: Nitta
authors.forename: Futoshi
authors.initials: F
authors.lastname: Taketani
authors.forename: Toyoaki
authors.initials: T
authors.lastname: Matsuura
authors.forename: Kimiko
authors.initials: K
authors.lastname: Morishita
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Hara
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011412:Propanolamines / Q000008:administration & dosage*
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011412:Propanolamines; C036089:nipradilol